Spero Therapeutics Inc
NASDAQ:SPRO
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.05
1.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SPRO stock under the Base Case scenario is 0.73 USD. Compared to the current market price of 1.29 USD, Spero Therapeutics Inc is Overvalued by 44%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Spero Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SPRO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Spero Therapeutics Inc
Balance Sheet Decomposition
Spero Therapeutics Inc
Current Assets | 122.2m |
Cash & Short-Term Investments | 63.5m |
Receivables | 55.5m |
Other Current Assets | 3.2m |
Non-Current Assets | 27.7m |
PP&E | 3.6m |
Other Non-Current Assets | 24m |
Current Liabilities | 45.6m |
Accounts Payable | 2.7m |
Accrued Liabilities | 11.7m |
Other Current Liabilities | 31.2m |
Non-Current Liabilities | 23.7m |
Other Non-Current Liabilities | 23.7m |
Earnings Waterfall
Spero Therapeutics Inc
Revenue
|
118.5m
USD
|
Operating Expenses
|
-102.9m
USD
|
Operating Income
|
15.6m
USD
|
Other Expenses
|
1.9m
USD
|
Net Income
|
17.5m
USD
|
Free Cash Flow Analysis
Spero Therapeutics Inc
USD | |
Free Cash Flow | USD |
Spero Therapeutics ended Q2 2024 with $63.5 million in cash. Revenue climbed to $10.2 million from $2.7 million in Q2 2023. This rise was driven by increased collaboration and grant revenues, primarily from agreements with GSK and BARDA. However, R&D expenses surged to $23.7 million from $9.5 million, aimed at advancing key clinical trials. Spero expects its cash, along with milestone payments, to fund operations until late 2025. Additionally, the company anticipates top-line data from its pivotal trials by next year, indicating continued focus on advancing SPR720 and tebipenem HBr【4:0†source】.
What is Earnings Call?
SPRO Profitability Score
Profitability Due Diligence
Spero Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Spero Therapeutics Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
SPRO Solvency Score
Solvency Due Diligence
Spero Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Score
Spero Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SPRO Price Targets Summary
Spero Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for SPRO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SPRO Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.
Contact
IPO
Employees
Officers
The intrinsic value of one SPRO stock under the Base Case scenario is 0.73 USD.
Compared to the current market price of 1.29 USD, Spero Therapeutics Inc is Overvalued by 44%.